Clinical trial
Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK…
NCT00052013 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00052013 |
|---|---|
| Title | Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584 |
| Official title | A Phase II Open-Label Study of Oral, Continuous, Once Daily PTK787/ZK 222584 in Patients With Von Hippel-Lindau Disease (VHL) and Hemangioblastoma (HB) |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Von Hippel-Lindau Disease, CNS Hemangioblastoma, Retinal Hemangioblastoma |
| Intervention type | Drug |
| Interventions | PTK787/ZK 222584 |
| Enrollment | 11 |
| Start date | Feb 1, 2003 |
| Primary completion | Jun 1, 2006 |
| First posted | Jan 22, 2003 |
| Last update posted | Mar 6, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: